Stockscreener 앱 받기
33.86
5.66%
-2.03
시간 외 거래:
33.88
0.02
+0.06%
Moderna Inc 주식(MRNA)의 최신 뉴스
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why - sharewise.com
Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010 - Yahoo Finance
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Record Searchlight
Biotech Co. Says HHS Infringed Patent With Moderna Vax Deal - Law360
What Analysts Are Saying About Moderna Stock - Benzinga
UBS Lowers Moderna (MRNA) Price Target to $34, Rating Changed to Neutral | MRNA Stock News - GuruFocus
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonald's, Moderna, and More - 24/7 Wall St.
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA) - The Globe and Mail
Bayer sues COVID vaccine makers over mRNA technology - ETPharma.com
My Top 5 Stocks to Buy in Early 2026 - The Motley Fool
Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - The Asheville Citizen Times
Bayer Sues Biontech and Pfizer Over Patents for Covid Vaccines - MarketScreener
Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties - Law360
Moderna, Inc. (MRNA) Issues Shareholder Letter Highlighting Stra - GuruFocus
Bayer Seeks Covid-Vaccine Royalties Over Crop-Technology Patent - Bloomberg Law News
UBS Downgrades Moderna (MRNA) Amid Revenue Concerns - GuruFocus
Moderna downgraded to neutral at UBS on questions over revenue growth - MSN
Moderna (NASDAQ:MRNA) Stock Price Up 8.6%Time to Buy? - MarketBeat
Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus - TechStock²
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine - The Globe and Mail
Moderna jumps 10% as BofA hikes target price - breakingthenews.net
Moderna rallies after BofA raises its price target to $24 from $21 - Sherwood News
BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating - MarketScreener
Moderna stock price target raised to $24 from $21 at BofA Securities - Investing.com UK
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine - Bartlesville Examiner-Enterprise
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches - Proactive financial news
Key facts: Moderna announces 2025 achievements; mRNA-1010 shows efficacy - TradingView — Track All Markets
CDC updates childhood vaccine schedule (PFE:NYSE) - Seeking Alpha
Jefferies reiterates Hold rating on Moderna stock, maintains $30 price target - Investing.com UK
Moderna, searching for a rebound, to seek approval of mRNA flu shot - BioPharma Dive
Moderna says aiming at 2025 projected revenue range of $1.6 bln to $2.0 bln - MarketScreener
Moderna (MRNA) Gains Ground Amid Flu Vaccine Regulatory Submissions - thebull.com.au
Moderna issues shareholder letter under Regulation FD disclosure - Investing.com
Moderna Highlights 2025 Progress and Strengthened Vaccine Portfolio - TipRanks
Moderna issues shareholder letter under Regulation FD disclosure By Investing.com - Investing.com South Africa
Moderna, Inc. Reports 2025 Achievements and 2026 Outlook - TradingView — Track All Markets
Moderna (MRNA) Advances Seasonal Flu Vaccine Regulatory Submissi - GuruFocus
Moderna (MRNA) Seeks Approval for New Influenza Vaccine - GuruFocus
Moderna (MRNA) Seeks Approval for New Flu Vaccine Targeting Olde - GuruFocus
Moderna seeks global approvals for flu shot - MSN
Moderna seeks global approvals for flu shot (MRNA:NASDAQ) - Seeking Alpha
Moderna files for approval of flu vaccine in four countries - StreetInsider
0.80%
4.56%
자본화:
|
볼륨(24시간):